IL191674A - Compastatin Patent Analogs - Google Patents

Compastatin Patent Analogs

Info

Publication number
IL191674A
IL191674A IL191674A IL19167408A IL191674A IL 191674 A IL191674 A IL 191674A IL 191674 A IL191674 A IL 191674A IL 19167408 A IL19167408 A IL 19167408A IL 191674 A IL191674 A IL 191674A
Authority
IL
Israel
Prior art keywords
compstatin analogs
potent compstatin
potent
analogs
compstatin
Prior art date
Application number
IL191674A
Other languages
English (en)
Hebrew (he)
Other versions
IL191674A0 (en
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of IL191674A0 publication Critical patent/IL191674A0/en
Publication of IL191674A publication Critical patent/IL191674A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL191674A 2005-11-28 2008-05-22 Compastatin Patent Analogs IL191674A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74020505P 2005-11-28 2005-11-28
PCT/US2006/045539 WO2007062249A2 (en) 2005-11-28 2006-11-28 Potent compstatin analogs

Publications (2)

Publication Number Publication Date
IL191674A0 IL191674A0 (en) 2009-02-11
IL191674A true IL191674A (en) 2015-04-30

Family

ID=37964706

Family Applications (2)

Application Number Title Priority Date Filing Date
IL191674A IL191674A (en) 2005-11-28 2008-05-22 Compastatin Patent Analogs
IL237915A IL237915B (en) 2005-11-28 2015-03-24 A method for preparing potent analogues of compstatin and using them to prepare a medicine to inhibit the activation of the complement system

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL237915A IL237915B (en) 2005-11-28 2015-03-24 A method for preparing potent analogues of compstatin and using them to prepare a medicine to inhibit the activation of the complement system

Country Status (15)

Country Link
US (5) US7888323B2 (enExample)
EP (4) EP3363810A1 (enExample)
JP (2) JP5302004B2 (enExample)
CN (3) CN102977191B (enExample)
BR (1) BRPI0619023B1 (enExample)
CA (2) CA2971349C (enExample)
DK (1) DK1960422T3 (enExample)
ES (3) ES2677619T3 (enExample)
HR (1) HRP20120621T1 (enExample)
IL (2) IL191674A (enExample)
PL (1) PL1960422T3 (enExample)
PT (1) PT1960422E (enExample)
RS (1) RS52429B (enExample)
RU (2) RU2474586C2 (enExample)
WO (1) WO2007062249A2 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2373649T3 (es) * 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
DK1960422T3 (da) 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger
US8637325B2 (en) * 2009-02-16 2014-01-28 University Of Wyoming Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
US8664176B2 (en) * 2006-10-20 2014-03-04 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye
DK2148691T3 (en) 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
JP2009003429A (ja) * 2007-05-18 2009-01-08 Panasonic Corp アクチュエータ
WO2008153963A1 (en) * 2007-06-08 2008-12-18 The Trustees Of The University Of Pennsylvania Structure of compstatin-c3 complex and use for rational drug design
US8563259B2 (en) 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
KR20100094453A (ko) * 2007-10-02 2010-08-26 포텐시아 팔마큐티칼스, 인크. 겔로부터 콤스타틴 유사체의 지속적 운반
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
AU2009298684B2 (en) * 2008-09-30 2015-11-19 Konstantinos Ritis Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
ES2655389T3 (es) * 2009-05-01 2018-02-19 The Trustees Of The University Of Pennsylvania Compstatina modificada con esqueleto peptídico y modificaciones c-terminales
US20110104154A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2012040259A2 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
EP2621538B1 (en) * 2010-09-28 2015-12-16 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
US20140219999A1 (en) 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
JP6522337B2 (ja) 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
EP3524258B1 (en) 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2013036778A2 (en) * 2011-09-07 2013-03-14 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
US20160067357A1 (en) * 2012-08-17 2016-03-10 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
PT2920201T (pt) 2012-11-15 2020-04-03 Apellis Pharmaceuticals Inc Análogos de compstatina de longa ação e composições e métodos relacionados
US20160194359A1 (en) * 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US9512180B2 (en) 2012-12-19 2016-12-06 The Regents Of The University Of California Compstatin analogs
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
MX382900B (es) 2013-12-12 2025-03-13 Alnylam Pharmaceuticals Inc COMPOSICIONES DE ÁCIDO RIBONUCLEICO DE INTERFERENCIA (ARNi) CONTRA EL COMPONENTE DEL COMPLEMENTO Y MÉTODOS PARA SU USO.
WO2015142701A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
US10597582B2 (en) 2014-12-23 2020-03-24 Multi-Chem Group, Llc Acrylate-based sulfur scavenging agents for use in oilfield operations
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
MX392574B (es) 2015-10-07 2025-03-24 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada para usarse en el tratamiento de trastornos oculares
CN118217402A (zh) 2016-10-17 2024-06-21 阿佩利斯制药有限公司 用于c3抑制的组合疗法
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
KR20190139931A (ko) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
CN111163767A (zh) 2017-08-02 2020-05-15 艾其林医药公司 治疗阵发性睡眠性血红蛋白尿症的治疗方案
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
MA51162A (fr) 2017-12-15 2020-10-21 Apellis Pharmaceuticals Inc Schémas posologiques et compositions et procédés associés
PE20201254A1 (es) * 2018-02-27 2020-11-16 Zp Spv 3 K/S Analogos de compstatina y sus usos medicos
MX2020010520A (es) 2018-04-06 2021-01-15 Univ Pennsylvania Analogos de compstatina con mayor solubilidad y mejores propiedades farmacocineticas.
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
CA3123583A1 (en) 2018-12-17 2020-06-25 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
AU2020245434A1 (en) 2019-03-22 2021-09-30 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
US11510939B1 (en) 2019-04-19 2022-11-29 Apellis Pharmaceuticals, Inc. RNAs for complement inhibition
JP7711044B2 (ja) 2019-08-27 2025-07-22 セトペー エスペーベー ３ コマンディト セルスカブ コンプスタチン類似体及びその医学的使用
JP7676377B2 (ja) 2019-10-22 2025-05-14 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分Ｃ３ ｉＲＮＡ組成物およびその使用方法
JP2023515073A (ja) 2020-02-20 2023-04-12 アキリオン ファーマシューティカルズ， インコーポレーテッド 補体因子ｄ媒介障害の処置用のヘテロアリール化合物
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
MX2022013606A (es) 2020-04-30 2023-01-16 Alnylam Pharmaceuticals Inc Composiciones de ácido ribonucleico interferente (arni) del factor b de complemento (cfb) y métodos de uso de las mismas.
WO2021231470A1 (en) 2020-05-12 2021-11-18 Alexion Pharmaceuticals, Inc. Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria
US20230287051A1 (en) 2020-07-16 2023-09-14 Zp Spv 3 K/S Inhibitors of complement factor c3 and their medical uses
US20250171423A1 (en) 2020-09-23 2025-05-29 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
EP4274896A1 (en) 2021-01-05 2023-11-15 Alnylam Pharmaceuticals, Inc. Complement component 9 (c9) irna compositions and methods of use thereof
EP4401742A2 (en) 2021-09-17 2024-07-24 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
EP4423273A1 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
CN114605495A (zh) * 2022-04-20 2022-06-10 广州市乾相生物科技有限公司 一种乳四肽的合成方法
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof
WO2025229200A1 (en) 2024-05-03 2025-11-06 Bachem Holding Ag Manufacture of disulfide bonded peptides
WO2025245483A1 (en) * 2024-05-24 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods and compositions
CN119176856B (zh) * 2024-11-22 2025-03-18 杭州诺泰诺和生物医药科技有限公司 Pegcetacoplan的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
CA2081312A1 (en) 1990-04-23 1991-10-24 Rudi P. Labadie Cyclic peptides and their use
AU683158B2 (en) 1994-03-03 1997-10-30 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
GB9604865D0 (en) * 1996-03-07 1996-05-08 Imutran Ltd Modified proteins
CA2248772C (en) * 1996-03-13 2007-06-12 John D. Lambris Novel peptides which inhibit complement activation
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en) 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
AU4648197A (en) 1997-09-17 1999-04-05 Burnham Institute, The Peptides and peptidomimetics for inhibiting complement activation
EP1067950B1 (en) 1998-04-10 2008-05-14 Mayo Foundation For Medical Education And Research Neo-tryptophan
ES2373649T3 (es) * 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
WO2004026326A2 (en) 2002-09-20 2004-04-01 Stichting Katholieke Universiteit Antigen uptake receptor for candida albicans on dendritic cells
CN105582523B (zh) * 2005-10-08 2022-04-15 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
DK1960422T3 (da) * 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger

Also Published As

Publication number Publication date
CN101400692B (zh) 2013-01-02
PT1960422E (pt) 2012-08-16
US20080227717A1 (en) 2008-09-18
WO2007062249A2 (en) 2007-05-31
DK1960422T3 (da) 2012-08-13
AU2006318333A1 (en) 2007-05-31
IL191674A0 (en) 2009-02-11
EP2377877B1 (en) 2018-03-28
JP2013177403A (ja) 2013-09-09
US20170305971A1 (en) 2017-10-26
BRPI0619023A2 (pt) 2011-09-20
CN101400692A (zh) 2009-04-01
US7888323B2 (en) 2011-02-15
EP1960422B1 (en) 2012-05-30
RU2474586C2 (ru) 2013-02-10
PL1960422T3 (pl) 2012-11-30
JP5927139B2 (ja) 2016-05-25
US20120004393A1 (en) 2012-01-05
HK1124621A1 (en) 2009-07-17
US20160096866A1 (en) 2016-04-07
CN106188239B (zh) 2020-01-07
IL237915B (en) 2018-11-29
CA2971349A1 (en) 2007-05-31
JP5302004B2 (ja) 2013-10-02
RU2656102C2 (ru) 2018-05-31
CN106188239A (zh) 2016-12-07
EP2377878B1 (en) 2018-03-28
CN102977191A (zh) 2013-03-20
HRP20120621T1 (hr) 2012-09-30
EP2377878A1 (en) 2011-10-19
BRPI0619023B1 (pt) 2022-09-27
ES2390828T3 (es) 2012-11-16
WO2007062249A3 (en) 2007-09-13
CN102977191B (zh) 2016-08-10
EP1960422A2 (en) 2008-08-27
ES2677619T3 (es) 2018-08-03
US20190016758A1 (en) 2019-01-17
CA2631443C (en) 2017-09-19
JP2009517476A (ja) 2009-04-30
US9169307B2 (en) 2015-10-27
CA2631443A1 (en) 2007-05-31
EP2377877A1 (en) 2011-10-19
CA2971349C (en) 2020-09-08
ES2677947T3 (es) 2018-08-07
RU2008126232A (ru) 2010-01-10
RU2012147267A (ru) 2014-05-20
RS52429B (sr) 2013-02-28
EP3363810A1 (en) 2018-08-22

Similar Documents

Publication Publication Date Title
IL191674A0 (en) Potent compstatin analogs
ZA200700357B (en) Tetrapetide analogs
GB2441403B (en) Rocker switch
ZA200904445B (en) Cyclopamine analogs
IL189235A0 (en) Improved aerosol
IL187919A0 (en) 4c
IL190286A0 (en) New cyclic peptide compounds
EP1841430A4 (en) SUBSTITUTED PYRIDAZINYL AND PYRIMIDINYL-CHINOLIN-4-YLAMINE ANALOGUE
GB2429966B (en) Shaft-ring gripper
EP1945258A4 (en) FDT RELATED COMPOUNDS AND THEIR ANALOGUES
ZA200802756B (en) Aerosolformulation for inhalation
GB2432258B (en) Switch
AP2007003894A0 (en) Tetrapeptide analogs
EP1862192A4 (en) INHALER
EP1874676A4 (en) SEPARATION STRUCTURE
SI1960422T1 (sl) Visokoaktivni analogi kompstatina
GB0614693D0 (en) Packet
GB0523098D0 (en) Antitumoral compounds
GB2432189B (en) Stays
AU2016202286A1 (en) Potent compstatin analogs
GB0518569D0 (en) Switch arrangement
GB0515673D0 (en) Antitumoral compounds
GB2421720B (en) Cantilever linkspan
TWM300860U (en) Switch
AU3792P (en) Exceltas Bromus coloratus

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed